AT 193
Alternative Names: AT-193Latest Information Update: 25 Mar 2024
At a glance
- Originator Azora Therapeutics
- Class Anti-inflammatories; Indoles; Skin disorder therapies; Small molecules
- Mechanism of Action Aryl hydrocarbon hydroxylase inhibitors; Aryl hydrocarbon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hidradenitis suppurativa; Psoriasis
- Preclinical Atopic dermatitis
Most Recent Events
- 15 Mar 2024 Azora Therapeutics completes a phase I clinical trials in Hidradenitis suppurativa (In adults, In the elderly) in Australia (Topical) (NCT04989517)
- 21 Dec 2023 Preclinical trials in Atopic dermatitis in USA (Topical), prior to December 2023 (Azora Therapeutics pipeline, December 2023)
- 01 Dec 2021 Phase-I clinical trials in Psoriasis in Australia (Topical) (NCT05072886)